20:22:41 EST Thu 19 Nov 2026
Enter Symbol
or Name
USA
CA



HYTN Innovations, Peptide Development close arrangement

2026-11-19 18:50 ET - News Release

See News Release (C-HYTN) HYTN Innovations Inc

Mr. Elliot McKerr of HYTN INNOVATIONS INC. AND PEPTIDE DEVELOPMENT LABS INC. ANNOUNCE CLOSING OF THE ARRANGEMENT AND CONCURRENT FINANCING

HYTN Innovations Inc. and Peptide Development Labs Inc. (PDL) have closed their previously announced arrangement effective at 12:01 a.m. on Nov. 17, 2026.

Arrangement

Under the statutory plan of arrangement involving HYTN and PDL, the shareholders of HYTN received common shares of PDL by way of a share exchange, pursuant to which each existing share of HYTN held at the effective time was exchanged for one new share of HYTN and 0.0555555555555556 of a PDL common share.

The Canadian Securities Exchange granted conditional acceptance of the arrangement on Nov. 11, 2026. The listing of the PDL common shares on the CSE under the symbol PEPT is subject to PDL meeting the listing requirements of the CSE, and PDL anticipates being listed on Nov. 20, 2026.

Concurrent financing

Concurrent with closing of the arrangement, PDL completed a non-brokered private placement for gross proceeds of approximately $3-million through the issuance of six million units of PDL at an issue price of 50 cents per PDL unit. Each PDL unit shall entitle the holder thereof to one PDL common share and one-half of one PDL common share purchase warrant. Each whole PDL warrant shall be exercisable for a period of 24 months for one PDL common share at an exercise price of 75 cents.

The net proceeds from the concurrent financing will be used to pursue the development milestones set out in HYTN's management information circular dated Oct. 16, 2026, including qualification and product set-up, engineer and validation, regulatory and clinical readiness, and formal clinical development.

All securities issued under the concurrent financing are subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities laws.

Stock symbols

New HYTN common shares will trade on the CSE under HYTN's current ticker symbol of HYTN. The Cusip number assigned to the new HYTN common shares is 40443L203 (ISIN: CA40443L203).

Once listed, the PDL common shares will trade on the CSE under the ticker symbol PEPT. The Cusip number assigned to the PDL common shares is 713467108 (ISIN: CA713467108).

Trading information

It is expected that the PDL common shares will begin trading on the CSE on Nov. 20, 2026.

Where existing HYTN common shares (Cusip No.: 40443L) are held through a broker, such broker, or the depositary with which the broker holds such HYTN common shares, will be responsible for dealing with the exchange of these HYTN common shares for new HYTN common shares and the distribution of PDL common shares on the HYTN shareholder's behalf.

HYTN has mailed letters of transmittal to all eligible registered shareholders. To receive direct registration system (DRS) statements representing new HYTN common shares and PDL common shares, registered shareholders must duly complete the letter of transmittal and either provide their DRS account number or surrender their existing certificates for HYTN common shares, as applicable, and deliver them to Odyssey Trust Company at the address shown on the letter of transmittal. Upon surrender to the depositary for cancellation of a certificate representing HYTN common shares (if any), together with a properly executed letter of transmittal, the registered shareholder will be entitled to receive, and the depositary will deliver to such holder, a statement representing the number of new HYTN common shares and the number (rounded down to the next lesser whole number, subject to the treatment of fractional PDL common shares under the terms of the plan of arrangement, attached as Schedule B to the circular) of new HYTN common shares and PDL common shares that such holder has the right to receive pursuant to the plan of arrangement and the surrendered certificate (if any) will be cancelled. The letter of transmittal was filed on HYTN's SEDAR+ profile on Oct. 22, 2026, and is available on SEDAR+.

About HYTN Innovations Inc.

HYTN formulates, manufactures, markets and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. HYTN's mission is to become the top provider of these products in all federally regulated markets. To achieve this, HYTN focuses on identifying market opportunities and quickly bringing its innovative products to market through its elevated development platform.

About Peptide Development Labs Inc.

PDL is a Canadian pharmaceutical development company focused on advancing investigational peptide-based drug candidates through established regulatory pathways. PDL's mission is to develop peptide candidates that may address defined areas of unmet clinical need within a conventional pharmaceutical framework. To achieve this, PDL focuses on advancing its investigational subcutaneous BPC-157 drug candidate for refractory ligament disorders through GMP-controlled (good manufacturing practices) supply, pharmaceutical quality systems, physician-led access, structured data generation and formal clinical development.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.